Changes in quality of life in people with Parkinson's disease left untreated at diagnosis

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 79, Issue 6, 2008, Pages 716-718

  Asimakopoulos, P ^a   Caslake, R ^b   Harris, C E ^b   Gordon, J C ^b   Taylor, K S M ^c   Counsell, C ^b  

^a CROSSHOUSE HOSPITAL   (United Kingdom)

^b UNIVERSITY OF ABERDEEN   (United Kingdom)

^c SOUTHERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BROMOCRIPTINE; CABERGOLINE; ENTACAPONE; LEVODOPA; PERGOLIDE; PRAMIPEXOLE; ROPINIROLE; SELEGILINE; ANTIPARKINSON AGENT;

AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; MALE; PARKINSON DISEASE; PARKINSON DISEASE QUESTIONNAIRE; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; UNIFIED PARKINSON DISEASE RATING SCALE; COHORT ANALYSIS; DAILY LIFE ACTIVITY; DISEASE COURSE; HEALTH STATUS; MIDDLE AGED; NEUROLOGIC EXAMINATION; OBSERVATION; PSYCHOLOGICAL ASPECT;

ACTIVITIES OF DAILY LIVING; AGED; AGED, 80 AND OVER; ANTIPARKINSON AGENTS; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HEALTH STATUS; HUMANS; MALE; MIDDLE AGED; NEUROLOGIC EXAMINATION; OBSERVATION; PARKINSON DISEASE; QUALITY OF LIFE;

EID: 44449166636     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp.2007.137190     Document Type: Article

References (12)

1. Olanow CW, Watts RL, Koller WC. An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment guidelines. Neurology 2001;56(Suppl 5):S1-S88.
2. Schapira AH, Obeso J. Timing of treatment initiation in Parkinson's disease: a need for reappraisal? Ann Neurol 2006;59:559-62.
3. Grosset D, Taurah L, Burn DJ, et al. A multicentre longitudinal observational study of changes in self reported health status in people with Parkinson's disease left untreated at diagnosis. J Neurol Neurosurg Psychiatry 2007;78:465-9.
4. Jenkinson C, Fitzpatrick R, Peto V, et al. The Parkinson's Disease Questionnaire (PDQ-39): development and validation of a Parkinson's disease summary index score. Age Ageing 1997;26:353-7.
5. Taylor KS, Counsell CE, Harris CE, et al. Pilot study of the incidence and prognosis of degenerative Parkinsonian disorders in Aberdeen, United Kingdom: methods and preliminary results. Mov Disord 2006;21:976-82.
6. Fahn S, Elton RL, UPDRS Development Committee. The Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Calne D, et al. eds. Recent developments in Parkinson's disease, vol 2. Florham Park, New Jersey: Macmillan Healthcare Information, 1987:153-63.
7. Hoehn MM, Yahr MD. Parkinsonism: onset, progression, and mortality. Neurology 1967;17:427-42.
8. PDMED website. Birmingham, UK: Birmingham Clinical Trials Unit, University of Birmingham. http://www.pdmed.bham.ac.uk/ (accessed 19 March 2008).
9. Yeh KC, August TF, Bush DF, et al. Pharmacokinetics and bioavailability of Sinemet CR: a summary of human studies. Neurology 1989;39(Suppl 2):25-38.
10. Kaakkola S. Clinical pharmacology, therapeutic use and potential of COMT inhibitors in Parkinson's disease. Drugs 2000;59:1233-50.
11. Minguez-Castellanos A, Escamilla-Sevilla F, Katati MJ, et al. Different patterns of medication change after subthalamic or pallidal stimulation for Parkinson's disease: target related effect or selection bias? J Neurol Neurosurg Psychiatry 2005;76:34-9.
12. Grosset K, Needleman F, Macphee G, et al. Switching from ergot to nonergot dopamine agonists in parkinson's disease: a clinical series and five-drug dose conversion table. Mov Disord 2004;19:1370-4.